文献速递造血干细胞移植与细胞治疗白血病

全身照射与化疗为基础的大剂量预处理方案对急性髓系白血病单倍体造血细胞移植结局的影响

Impact of total body irradiation- vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia.
PubMed 文献 · Am J Hematol · 2020-08-06

该研究纳入1008例接受首次单倍体造血细胞移植联合移植后环磷酰胺的急性髓系白血病患者,比较全身照射为基础(N=89)与化疗为基础(N=919)的大剂量预处理方案。多因素分析显示全身照射组总体慢性移植物抗宿主病风险升高(HR=1.95,95%CI 1.2-3.1,P<.01),但两组在复发、无白血病生存、非复发死亡、总体生存及无GVHD无复发生存方面无统计学差异。

要点

  • 全身照射组总体慢性GVHD发生率42% vs 化疗组27%(P<.01),多因素分析HR=1.95(95%CI 1.2-3.1,P<.01)。
  • 广泛型慢性GVHD发生率全身照射组9% vs 化疗组12%(P=.33)。
  • 两组在复发、无白血病生存、非复发死亡、总体生存及无GVHD无复发生存方面无统计学差异。

核心结论

  • 在急性髓系白血病患者接受单倍体造血细胞移植联合移植后环磷酰胺后,全身照射为基础与化疗为基础的大剂量预处理方案在主要移植结局方面无统计学差异。

研究设计与样本

  • 研究纳入1008例接受首次单倍体造血细胞移植联合移植后环磷酰胺的急性髓系白血病患者,其中全身照射为基础大剂量预处理组89例(9%),化疗为基础大剂量预处理组919例(91%)。

主要发现

  • 全身照射组患者较年轻(中位年龄38岁 vs 47岁,P<.01),且更可能接受骨髓移植物(57% vs 43%,P=.01)。
  • 2年总体慢性GVHD发生率全身照射组42% vs 化疗组27%(P<.01),广泛型慢性GVHD发生率全身照射组9% vs 化疗组12%(P=.33)。
  • 移植物失败报告于全身照射组2例(2%)与化疗组65例(7%)(P=.08)。
  • 研究期间死亡患者中,静脉闭塞病所致死亡报告于全身照射组1例(3%)与化疗组11例(3%)。
  • 多因素分析中,与化疗为基础大剂量预处理相比,全身照射与总体慢性GVHD风险升高相关(HR=1.95,95%CI 1.2-3.1,P<.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The optimal myeloablative conditioning (MAC) for patients undergoing haploidentical hematopoietic cell transplantation (haplo-HCT) is unknown. We studied the outcomes of total body irradiation (TBI) vs chemotherapy (CT) based MAC regimens in acute myeloid leukemia (AML) patients. The study included 1008 patients who underwent first haplo-HCT with post-transplant cyclophosphamide, following TBI (N = 89, 9%) or CT (n = 919, 91%) based MAC. Patients in the TBI cohort were younger (median age, 38 vs 47 years, P < .01) and more likely to receive BM graft (57% vs 43%, P = .01). Two-year overall chronic GVHD (cGVHD) incidence was 42% vs 27% (P < .01) and extensive cGVHD incidence was 9% vs 12% (P = .33) in TBI and CT cohorts, respectively. Graft failure was reported in two (2%) TBI- and 65 (7%) CT-MAC recipients (P = .08). Death from veno-occlusive disease was reported in one (3%) TBI and 11 (3%) CT patients who died during the study period. In the multivariate analysis, TBI was associated with increased risk for overall cGVHD (hazard ratio = 1.95, 95% confidence interval:1.2-3.1, P < .01) compared to CT-based MAC. The choice of conditioning regimen did not impact relapse incidence, leukemia-free survival, non-relapse mortality, overall survival or GVHD-relapse-free survival in multivariate analysis. In conclusion, major transplant outcomes were not statistically different between TBI-based MAC and CT-based MAC in patients with AML after haplo-HCT/PTCy.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Dholaria B, Labopin M, Angelucci E, et al. Impact of total body irradiation- vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia. Am J Hematol. 2020. PMID: 32656791. doi:10.1002/ajh.25934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。